BioSpace News Archive

GlaxoSmithKline has declined all three of Unilever PLC’s offers to acquire its Consumer Healthcare business, saying that the proposal undervalued the division’s present and further worth.

Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced the initiation of patient dosing in its Phase 2b clinical trial of XW003 in patients with obesity.

Select Medical Holdings Corporation (“Select Medical,” “we,” “us,” or “our”) (NYSE: SEM) today announced an estimate of certain results for its full year ended December 31, 2021 in advance of the announcement of actual results. Select Medical will release its actual financial results for its fourth quarter and full year ended December 31, 2021.

AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application of ENHERTU® for the treatment of adult patients in the US with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen.

MedX Health Corp., a global leader in teledermatology, is pleased to announce that MedX’s leading-edge DermSecure® screening platform services are being offered in Empower’s The Medi-Collective locations across Ontario, Canada.

Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it will release its financial results for the fourth quarter and year ended December 31, 2021.

Medicenna Therapeutics Corp., a clinical stage immuno-oncology company, announced that Mann Muhsin has resigned as Chief Medical Officer of the Company to assume a position closer to home.

extractX Ltd. (“ extractX ” or the “ Company” ), today announced financial results for the Company and its subsidiary extractX Incorporated (“ EXI ”) as at and for the nine months ended September 30, 2021.

CANbridge Pharmaceuticals Inc. announced that the Chinese National Medical Products Administration has accepted the New Drug Application for CAN108 ) for the treatment of cholestatic pruritus in patients with Alagille syndrome 1 year of age and older.

Abbisko Therapeutics Co., Ltd., a subsidiary of Abbisko Cayman Limited, announced that it has entered into a worldwide collaboration and exclusive licensing agreement with Eli Lilly and Company for the further discovery, development and potential commercialization of novel molecules against an undisclosed target for cardiometabolic diseases with critical unmet medical needs.